About 40 years have passed since the classical glycosidase inhibitor nojirimycin was
discovered from the cultured broth of the Streptomyces species. Since then, over 100 …

Inherent or acquired drug resistance, which frequently characterizes cancer cells, is caused
by multiple mechanisms, including dysfunctional metabolism of the lipid second messenger …

The imino sugar deoxynojirimycin and its alkylated derivatives are inhibitors of the N-linked
oligosaccharide processing enzymes alpha-glucosidase I and II. These compounds are …

Abdominal aortic aneurysm (AAA) is a lethal cardiovascular disease, and there is no proven
drug treatment for this condition. In this study, by using the Connectivity Map (CMap) …

Multidrug-resistant (MDR) tumors and cancer cell lines demonstrate a wide variety of
biochemical changes. In this study we used drug-sensitive wild-type (wt) cancer cell lines …

In HeLa cells, Shiga toxin B-subunit is transported from the plasma membrane to the
endoplasmic reticulum, via early endosomes and the Golgi apparatus, circumventing the …

Polycystic kidney disease (PKD) represents a family of genetic disorders characterized by
renal cystic growth and progression to kidney failure. No treatment is currently available for …

Previous work has led to the identification of inhibitors of glucosylceramide synthase, the
enzyme catalyzing the first glycosylation step in the synthesis of glucosylceramide-based …

In this study, we have examined the cellular and biochemical activities of the ceramide
analog (1S, 2R)-Derythro-2-(N-myristoylamino)-1-phenyl-1-propanol (Derythro-MAPP) …

An approach to treating Gaucher disease is substrate inhibition therapy which seeks to
abate the aberrant lysosomal accumulation of glucosylceramide. We have identified a novel …